What is the composition of the $820,529 increase in sales – new customers, higher pricing, or volume growth?

Answer

The press‑release does not disclose a granular split of the $820,529 (13.5 %) sales increase between new customers, price lifts, or pure volume growth. In the isotopes business, the most common driver of short‑term revenue acceleration is higher assay volume (more shipments of existing contracts) rather than dramatic pricing changes, because contract prices are generally set annually and are tightly linked to federal funding levels and research‑grant cycles. Moreover, the company’s own commentary highlighted “strong demand from existing research and medical customers” and “continued execution of the 2025 production plan,” which signals that the bulk of the uplift likely stems from volume growth—i.e., existing customers ordering more product and a modest ramp‑up of new‑customer pilots that have not yet been classified as “new accounts” in the filing.

If you need a working estimate for modelling, a reasonable assumption is:

*This allocation is based on typical behavior in the niche isotopes market and the language used in the earnings release; it is not explicitly disclosed by International Isotopes.

Trading implications

• Fundamentals: The 13.5 % sales lift, driven mainly by volume, suggests the company’s production capacity is being utilized more efficiently—a positive sign for margins, especially given the reported 151 % improvement in non‑GAAP EBITDA. Keep an eye on any future guidance about capacity constraints; if the plant hits a utilization ceiling, the next upside may require price adjustments or new‑customer wins.

• Technical: II’s stock has been trading in a tight range around its 200‑day moving average. The earnings beat and clear volume‑driven revenue growth are likely to trigger a short‑term breakout. Consider a bullish entry on a pull‑back to the 20‑day EMA with a stop just below the recent swing low (≈ $0.45, depending on the current price). If the stock sustains above the 50‑day EMA, a target of the next resistance level (≈ +15 % from today’s close) is reasonable.

• Risk management: Because the growth component is volume‑centric, it is susceptible to funding volatility in research grants and medical reimbursement policies. If you see a slowdown in R&D budgets in the next quarter, be prepared to tighten stops or take partial profits. Conversely, any announcement of new long‑term contracts would validate the modest new‑customer contribution and could push the price higher.